Literature DB >> 24275174

An approach to chemotherapy-associated toxicity.

Zhanna Livshits1, Rama B Rao, Silas W Smith.   

Abstract

The effects of chemotherapy in multiple organ systems may be challenging to discern from the sequelae of malignancy and systemic illnesses with concomitant immunocompromise. Chemotherapeutic agents typically affect multiple organ systems. Intrathecal medication errors may pose particularly devastating neurologic consequences and death, often requiring emergent intervention. This article provides an overview of commonly used chemotherapeutic drugs, indications for use, their adverse effects by organ system, and the management of commonly encountered toxicities. Intrathecal medication errors and specific antidotes are discussed in pertinent management sections. Emergency department management should focus on rapid patient assessment, immediate intervention following intrathecal medication errors, exclusion of infection, and excellent supportive care.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adverse effects; Cancer; Chemotherapy; Extravasation; Toxicity

Mesh:

Substances:

Year:  2014        PMID: 24275174     DOI: 10.1016/j.emc.2013.09.002

Source DB:  PubMed          Journal:  Emerg Med Clin North Am        ISSN: 0733-8627            Impact factor:   2.264


  38 in total

1.  An evolving function of DNA-containing exosomes in chemotherapy-induced immune response.

Authors:  Paul Kurywchak; Raghu Kalluri
Journal:  Cell Res       Date:  2017-05-19       Impact factor: 25.617

2.  Combination effect of curcumin with docetaxel on the PI3K/AKT/mTOR pathway to induce autophagy and apoptosis in esophageal squamous cell carcinoma.

Authors:  Lian Deng; Xiaoran Wu; Xiongjie Zhu; Zhongjian Yu; Zhile Liu; Jinting Wang; Yanfang Zheng
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

Review 3.  Peptides and peptidomimetics as immunomodulators.

Authors:  Ameya S Gokhale; Seetharama Satyanarayanajois
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

4.  Troubleshooting an unusual complication following intrathecal chemotherapy delivered via Ommaya catheter: A case report.

Authors:  David J Mauler; Kent R Richter; Sarah Merrill; Cristina Valencia-Sánchez; Chandan Krishna; Maciej M Mrugala
Journal:  Mol Clin Oncol       Date:  2020-04-22

Review 5.  An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides.

Authors:  Jiang Cheng; Zhi-Wei Zhou; Hui-Ping Sheng; Lan-Jie He; Xue-Wen Fan; Zhi-Xu He; Tao Sun; Xueji Zhang; Ruan Jin Zhao; Ling Gu; Chuanhai Cao; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2014-12-17       Impact factor: 4.162

6.  Exosomes as drug delivery vehicle and contributor of resistance to anticancer drugs.

Authors:  Mahendran Chinnappan; Akhil Srivastava; Narsireddy Amreddy; Mohammad Razaq; Vipul Pareek; Rebaz Ahmed; Meghna Mehta; Jo Elle Peterson; Anupama Munshi; Rajagopal Ramesh
Journal:  Cancer Lett       Date:  2020-05-19       Impact factor: 8.679

Review 7.  Small extracellular vesicles in cancer.

Authors:  Komal Abhange; Amy Makler; Yi Wen; Natasha Ramnauth; Wenjun Mao; Waseem Asghar; Yuan Wan
Journal:  Bioact Mater       Date:  2021-04-07

Review 8.  Polysaccharide-based nanomedicines for cancer immunotherapy: A review.

Authors:  Yujun Zeng; Yufan Xiang; Ruilong Sheng; Helena Tomás; João Rodrigues; Zhongwei Gu; Hu Zhang; Qiyong Gong; Kui Luo
Journal:  Bioact Mater       Date:  2021-03-18

9.  Clinical application of intrathecal gadobutrol for assessment of cerebrospinal fluid tracer clearance to blood.

Authors:  Per K Eide; Espen Mariussen; Hilde Uggerud; Are H Pripp; Aslan Lashkarivand; Bjørnar Hassel; Hege Christensen; Markus Herberg Hovd; Geir Ringstad
Journal:  JCI Insight       Date:  2021-05-10

10.  Cardiotoxicity and Cardiac Monitoring Among Anthracycline-Treated Cancer Patients: A Retrospective Cohort Study.

Authors:  Hadeel Alkofide; Lamya Alnaim; Nora Alorf; Ward Alessa; Ghada Bawazeer
Journal:  Cancer Manag Res       Date:  2021-06-29       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.